| Market Cap | 99.75M | P/E | - | EPS this Y | 43.60% | Ern Qtrly Grth | - |
| Income | -14.91M | Forward P/E | -4.66 | EPS next Y | 15.80% | 50D Avg Chg | 7.00% |
| Sales | 6.56M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -13.00% |
| Dividend | N/A | Price/Book | 2.09 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 2.00 | Quick Ratio | 7.02 | Shares Outstanding | 27.86M | 52W Low Chg | 27.00% |
| Insider Own | 65.17% | ROA | -21.63% | Shares Float | 7.67M | Beta | 1.57 |
| Inst Own | 26.44% | ROE | -35.85% | Shares Shorted/Prior | 96.99K/198.80K | Price | 3.59 |
| Gross Margin | -153.48% | Profit Margin | -227.40% | Avg. Volume | 18,341 | Target Price | 5.00 |
| Oper. Margin | 29.89% | Earnings Date | Nov 7 | Volume | 7,977 | Change | -7.71% |
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.